This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on our current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors,
which include, but are not limited to, any adverse impact on our business or the global economy and financial markets, generally, from the global
COVID-19 pandemic, and the risk factors disclosed in our periodic and current reports filed with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent reports. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update these forward-looking statements except as required by law.
PUMA's Pharmacy and Distributor Network
Hub Services
Specialty Pharmacy Network (SP)
Acaria Health
Accredo
CVS
ONCO 360
Optum /
Patients
Biologics
Diplomat
Sites of Care
Specialty Distributor Network (SD)
Academic Hospitals
McKesson
Community Hospitals
ASD/Oncology Supply
Physician Practices
Cardinal Health
Others (VA, DOD)
DMS Pharmaceutical Group
Inc.
Copyright 2021 Puma Biotechnology
3
~$43 Million net NERLYNX revenue in Q3'21
Quarterly Net Revenue (in $MM)
61.1
58.7
50.8
52.6
53.8
53.5
50.0
48.6
48.8
49.3
48.9
45.6
45.8
43.4
36.0
20.1
6.1
Copyright 2021 Puma Biotechnology
4
2,947 Ex-factory bottles were sold in Q3'21
Bottles Sold (SP + SD) by Quarter
5,538
4,799
4,936
4,791
4,935
4,696
4,452
4,035
3,517
3,728
3,611
3,585
3,354
3,247
2,947
2,137
675
Includes Commercial SP and SD
Copyright 2021 Puma Biotechnology
5
Attachments
Original document
Permalink
Disclaimer
Puma Biotechnology Inc. published this content on 04 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 November 2021 22:11:01 UTC.
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.
PUMA BIOTECHNOLOGY, INC. 
